Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of dupilumab in pediatric atopic dermatitis
2015-001396-40Phase 3Active
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dupilumab in atopic dermatitis (AD), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Incidence and rate of treatment-emergent adverse events. Started Jun 2015; status: active.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2015-001396-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001396-40.